Literature DB >> 9630003

Studies on benzodiazepines and opioids administered alone and in combination in rhesus monkeys: ventilation and drug discrimination.

L R Gerak1, M R Brandt, C P France.   

Abstract

Benzodiazepines and opioids are co-administered recreationally as well as clinically; in the current study, the ventilatory-depressant and discriminative stimulus effects of several benzodiazepines and opioids were examined alone and in combination in order to evaluate any interaction between agonists from these pharmacological classes. The benzodiazepines alprazolam, diazepam, flunitrazepam, lorazepam, midazolam and triazolam and the opioids morphine and fentanyl decreased ventilation (V(E)) in monkeys breathing either air or 5% CO2 in air, although decreases in ventilation produced by opioids were greater in magnitude than decreases produced by benzodiazepines. Flumazenil antagonized the ventilatory-depressant effects of flunitrazepam and triazolam and not those of fentanyl; naltrexone antagonized the ventilatory-depressant effects of fentanyl and not those of flunitrazepam or triazolam. Interactions between the ventilatory-depressant effects of agonists from the two classes were less than additive. In monkeys receiving 3.2 mg/kg per day of morphine and discriminating 0.01 mg/kg naltrexone, neither flunitrazepam nor triazolam substituted for naltrexone; in morphine-deprived monkeys, morphine, and not flunitrazepam or triazolam, reversed naltrexone-lever responding. Moreover, benzodiazepines did not modify the discriminative stimulus effects of naltrexone in morphine-treated monkeys or of morphine in morphine-deprived monkeys. In contrast to studies showing synergism between benzodiazepines and opioids, the current study suggests that, under some conditions, combinations of these drugs can be administered without enhancing the ventilatory-depressant effects of either class of drugs or the discriminative stimulus effects of opioids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630003     DOI: 10.1007/s002130050606

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.

Authors:  Lisa R Gerak; David R Maguire; James H Woods; Stephen M Husbands; Alex Disney; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2018-11-21       Impact factor: 4.030

2.  Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys.

Authors:  Peter F Weed; Lisa R Gerak; Charles P France
Journal:  Eur J Pharmacol       Date:  2018-05-26       Impact factor: 4.432

3.  Dyspnoea associated with anxiety--symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients.

Authors:  Katri Elina Clemens; Eberhard Klaschik
Journal:  Support Care Cancer       Date:  2010-12-14       Impact factor: 3.603

4.  The discriminative stimulus effects of midazolam are resistant to modulation by morphine, amphetamine, dizocilpine, and γ-butyrolactone in rhesus monkeys.

Authors:  Xiang Bai; Charles P France; Lisa R Gerak
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

5.  Impulsivity and drugs of abuse: a juice-reinforced operant procedure for determining within-session delay discounting functions in rhesus monkeys.

Authors:  David R Maguire; Jun-Xu Li; Charles P France
Journal:  J Pharmacol Toxicol Methods       Date:  2012-08-27       Impact factor: 1.950

6.  Comparison of the effects of ketamine and fentanyl-midazolam-medetomidine for sedation of rhesus macaques (Macaca mulatta).

Authors:  Henri G M J Bertrand; Yvette C Ellen; Stevie O'Keefe; Paul A Flecknell
Journal:  BMC Vet Res       Date:  2016-06-08       Impact factor: 2.741

7.  The influence of opioids and nonopioid central nervous system active medications on central sleep apnea: a case-control study.

Authors:  Ronald Gavidia; Amara Emenike; Anran Meng; Erica C Jansen; Shelley Hershner; Cathy Goldstein; Judy Fetterolf; Galit Levi Dunietz
Journal:  J Clin Sleep Med       Date:  2021-01-01       Impact factor: 4.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.